

phenotype prediction from genotype (version 3.4)

## I. General information

Patient:		Study Id:	
Birth date:		Viral load:	
Sample received:		Sample collected:	
Sample ID:	45	Predicted subtype:	B (100%)
Sample type:		Report date:	October 6, 2018
Physician:		Reported by:	

## II. Substitutions (relative to the reference strain HXB2)

Protease:	V3I, L10F, V11I, I13I/V, K20R, V32I, L33F, E35D, M36I, S37Q, M46I, I47V, I54L, R57K, Q58E, D60E, I62V, L63P, A71V, G73S, V77T, I84V, L89V, L90M, I93L
Reverse transcriptase:	

## III. Phenotype prediction

Drug	Resistance Factor RF (*)	z-score	Scored Positions (**)
ZDV	0	0	
ddI	0	0	
d4T	0	0	
3TC	0	0	
ABC	0	0	
TDF	0	0	
NVP	0	0	
EFV	0	0	
ETR (***)	Susceptible		
RPV (***)	Susceptible		
SQV	64.598	11.975	48G <u>84V</u> <u>74T</u> 88N <u>90M</u> <u>47V</u> <u>53F</u> 95C <u>26T</u> <u>11I</u> <u>1P</u> 80T <u>34E</u> <u>54L</u> <u>97L</u>
IDV	112.897	12.25	82V <u>54L</u> <u>88N</u> <u>90M</u> <u>29D</u> <u>1P</u> <u>84V</u> <u>21E</u> <u>65E</u> <u>32I</u> <u>46I</u> <u>85I</u> <u>30D</u> <u>73S</u> <u>78G</u>
NFV	315.989	12.988	88N <u>30D</u> <u>90M</u> <u>84V</u> <u>82V</u> <u>97L</u> <u>68G</u> <u>46I</u> <u>31T</u> <u>75V</u> <u>74T</u> <u>54L</u> <u>5L</u> <u>2Q</u> <u>1P</u>
APV	1003.993	21.519	<u>33F</u> <u>76L</u> <u>50I</u> <u>84V</u> <u>32I</u> <u>89V</u> <u>46I</u> <u>54L</u> <u>85I</u> <u>47V</u> <u>10F</u> <u>22A</u> <u>63P</u> <u>1P</u> <u>82V</u>
LPV	212.611	15.641	82V <u>50I</u> <u>46I</u> <u>84V</u> <u>33F</u> <u>76L</u> <u>54L</u> <u>89V</u> <u>22A</u> <u>10F</u> <u>7Q</u> <u>63P</u> <u>24L</u> <u>47V</u> <u>25D</u>
TPV	10.052	4.979	<u>69H</u> <u>46I</u> <u>48G</u> <u>84V</u> <u>90M</u> <u>47V</u> <u>72I</u> <u>15I</u> <u>91T</u> <u>71V</u> <u>54L</u> <u>73S</u> <u>82V</u> <u>74T</u> <u>88N</u>
DRV	127.737	12.854	<u>47V</u> <u>33F</u> <u>84V</u> <u>76L</u> <u>74T</u> <u>43K</u> <u>65E</u> <u>10F</u> <u>93L</u> <u>48G</u> <u>32I</u> <u>15I</u> <u>7Q</u> <u>62V</u> <u>8R</u>
ATV	311.536	17.125	48G <u>84V</u> <u>82V</u> <u>90M</u> <u>4T</u> <u>33F</u> <u>88N</u> <u>7Q</u> <u>73S</u> <u>24L</u> <u>76L</u> <u>45K</u> <u>32I</u> <u>54L</u> <u>93L</u>


(\*) based on LIBSVM, Copyright (c) 2000, Chih-Chung Chang and Chih-Jen Lin

(\*\*) Positions are ordered according to their impact on the phenotype prediction. Differences with respect to HXB2 are underlined. Positions shown in red and in green contribute to an increase or decrease in resistance, respectively. At most 15 positions are shown for each drug.

(\*\*\*) Resistance predictions and scored mutations for ETR and RPV were performed with rules-based drug-resistance interpretation models by HIV-GRADE (<http://www.hiv-grade.de>)

## IV. Interpretation

Patient:	Birth date:	Sampling date:
Current therapy:		Viral load:



Legend: █ susceptible   █ intermediate   █ resistant

(\*)number of standard deviations above mean of drug naive patients. Negative z-scores may indicate hypersusceptibility.

NRTIs/NtRTI:

NNRTIs:

PIs:

Previous genotypes:

date

signature